Sector Expert: Dorman Followwill

Frost & Sullivan Inc

Image: Dorman Followwill

A founding member of Frost & Sullivan's global Growth Consulting enterprise, Dorman Followwill has more than 30 years of experience, both in the field of management consulting and as a manager in the nonprofit sector. He began his career as a management consultant with Marakon Associates in San Francisco. He has worked for Frost & Sullivan for more than 16 years, in both the U.S. and in Europe, having overseen the global Growth Consulting enterprise in its infancy, as well as managing the most profitable business unit in the 54-year history of the firm. Followwill currently serves as a partner on the Partner Leadership Team overseeing the European practice as a whole, as well as managing the Healthcare practice in Europe, Israel and Africa. He has managed a wide variety of consulting engagements with Frost & Sullivan, including acquisition analyses and emerging market analyses for GE Healthcare, long-term strategic planning projects for a division of Merck, quarterly product tracking to the brand level over more than 11 years for Bayer, market size and epidemiology analysis for GlaxoSmithKline, multiple product analyses for Philips Medical, as well as a host of other projects for clients such as 3M, Medtronic, Johnson & Johnson, Siemens Medical Systems, IBM, Hewlett Packard, Roche Diagnostics, Hitachi and many others. He has executed coaching workshops focused on mega trends-driven innovation over the past five years with Daiichi Sankyo, Roche Diagnostics, Merck Millipore, Honeywell, Endress + Hauser, Shell, GE Healthcare and Hitachi. Followwill had a bachelor's degree in management of organizations from Stanford University.



Recent Quotes

"If everything plays out through the clinical trials process, that will position SRNE as one of the greatest biotechs in history."

The Life Sciences Report Interview with Dorman Followwill (1/6/16)
more >

"INO has a very interesting technology; the therapy has a two-sided aspect to it."

The Life Sciences Report Interview with Dorman Followwill (1/6/16)
more >



Due to permission requirements, not all quotes are shown.